Michael Hufford

Co-Founder and CEO

LyGenesis

Michael Hufford, PhD is the CEO of LyGenesis, an organic regeneration company using lymphatic bioreactors. He is an entrepreneur and drug developer with experience developing small molecules (Cypress Bioscience), biologics (Amylin Pharmaceuticals), as well as drug delivery technologies (e-Nicotine Technology). He has consulted extensively to drug development programs in a wide variety of therapeutic areas, spanning clinical trial design (as an EIR at the University of Pittsburgh), patient-reported outcomes (invivodata), neuropsychological outcomes (NeuroCog Trials), and Rx-to-OTC switch programs (PinneyAssociates). His philanthropic work includes co-founding and serving as the CEO of Harm Reduction Therapeutics, a nonprofit pharmaceutical company focused on bringing low-cost naloxone to the OTC market. Michael earned his undergraduate degree from Purdue University, and his master’s and doctoral degrees in clinical psychology from the University of Pittsburgh before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School.

Michael Hufford

Co-Founder and CEO

LyGenesis

Michael Hufford, PhD is the CEO of LyGenesis, an organic regeneration company using lymphatic bioreactors. He is an entrepreneur and drug developer with experience developing small molecules (Cypress Bioscience), biologics (Amylin Pharmaceuticals), as well as drug delivery technologies (e-Nicotine Technology). He has consulted extensively to drug development programs in a wide variety of therapeutic areas, spanning clinical trial design (as an EIR at the University of Pittsburgh), patient-reported outcomes (invivodata), neuropsychological outcomes (NeuroCog Trials), and Rx-to-OTC switch programs (PinneyAssociates). His philanthropic work includes co-founding and serving as the CEO of Harm Reduction Therapeutics, a nonprofit pharmaceutical company focused on bringing low-cost naloxone to the OTC market. Michael earned his undergraduate degree from Purdue University, and his master’s and doctoral degrees in clinical psychology from the University of Pittsburgh before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School.